Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STRIDE + Lenvatinib vs STRIDE in Unresectable Hepatocellular Carcinoma
NCT06880523Phase 2Recruiting
- Sponsor
- Canadian Cancer Trials Group
- Start
- Oct 2025
- Primary completion
- Jan 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of lenvatinib in hepatocellular carcinoma (HCC) (2 arms), sponsored by Canadian Cancer Trials Group. Primary endpoint: Progression-Free Survival at 32 months. Started Oct 2025; status: recruiting.
02
Drugs
lenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06880523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06880523.